ClinicalTrials.gg
Not yet recruitingNCT07863765Updated Oct 7, 2026

Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

A Phase 2 interventional study of Biopsy Procedure and Biospecimen Collection in Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma and Metastatic Thyroid Gland Anaplastic Carcinoma, sponsored by Northwestern University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Northwestern University · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States — 5 open to participants now, 14 under way, none of them phase 3. Thyroid Carcinoma, Anaplastic · United States.

Planned enrollment
13th of 47
56 · median 26
Started
2027
the only one that year
Phase 2
29 of 50
4 open now
Primary completion
2030-05
later than 12 of 13 live
Registered
49th of 50
by date
Lead sponsor
2 of 50
Northwestern University

Among the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, this one is the 13th largest by planned enrollment of the 47 interventional ones that give a count, is the only one that started in 2027, is one of 29 in phase 2, reaches primary completion later than 12 of the 13 other live ones, and was the 49th registered.

Thyroid Carcinoma, Anaplastic

87 studies on the registry are indexed under Thyroid Carcinoma, Anaplastic; 18 are open to participants now.

Browse Thyroid Carcinoma, Anaplastic studies →

Open to participants now

5 of the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Thyroid Carcinoma, Anaplastic studies recruiting now, 14 (100%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, or all of them as a file.
02

Study summary

This trial tests how well giving enfortumab vedotin works for the treatment of differentiated thyroid cancer that does not respond to treatment with radioiodine (refractory), anaplastic thyroid cancer, medullary thyroid cancer or NUT carcinoma that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate.

Read the detailed description

PRIMARY OBJECTIVE:

I. Assess efficacy of treatment with enfortumab vedotin (EV) in radioactive iodine refractory (RAIR) differentiated thyroid cancer (DTC), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and Nuclear Protein in Testis (NUT) carcinoma (NC) patients by evaluating the proportion of patients alive and without progression at 6 months.

SECONDARY OBJECTIVES:

I. Assess efficacy of treatment with enfortumab vedotin (EV) in RAIR DTC, ATC, MTC and NC patients by evaluating the objective response rate (ORR) by imaging.

II. Assess efficacy of treatment with enfortumab vedotin (EV) in RAIR DTC, ATC, MTC and NC patients by evaluating progression free survival.

III. Assess efficacy of treatment with enfortumab vedotin (EV) in RAIR DTC, ATC, MTC and NC patients by evaluating the overall survival time at 6 months.

IV. Assess efficacy of treatment with enfortumab vedotin (EV) in RAIR DTC, ATC, MTC and NC patients by evaluating the overall survival time.

V. Assess the safety and tolerability of EV monotherapy in patients with RAIR DTC, ATC, MTC and NC.

VI. Characterize the quality of life in RAIR DTC , ATC, MTC and NC patients treated with EV.

EXPLORATORY OBJECTIVES:

I. Assess immune cell landscape in EV treated patients. II. Assess expression of Nectin-4 in patients with RAIR DTC, ATC, MTC and NC. III. Next generation sequencing (NGS), biomarker analysis and optional single cell sequencing for patients with RAIR DTC, ATC, MTC and NC for assessment of response or failure to EV monotherapy.

OUTLINE:

Patients receive enfortumab vedotin intravenously (IV) on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan, x-ray imaging or magnetic resonance imaging (MRI) and blood and urine sample collection throughout the study and optionally undergo biopsy at progression.

After completion of study treatment, patients are followed up at 30 days and every 3 months for 12 months.

03

Conditions studied

  • Metastatic Differentiated Thyroid Gland Carcinoma
  • Metastatic NUT Carcinoma
  • Metastatic Thyroid Gland Anaplastic Carcinoma
  • Metastatic Thyroid Gland Medullary Carcinoma
  • Refractory Differentiated Thyroid Gland Carcinoma
  • Stage III Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage III Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
  • Unresectable Differentiated Thyroid Gland Carcinoma
  • Unresectable NUT Carcinoma
  • Unresectable Thyroid Gland Anaplastic Carcinoma
  • Unresectable Thyroid Gland Medullary Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have or cytologically confirmed:

    • radioiodine (RAIR) differentiated thyroid cancer (DTC)\^A (including RAIR poorly differentiated thyroid cancer [PDTC])\^A

      • radioiodine refractory (RAIR) differentiated thyroid cancer (DTC\^1), (including RAIR poorly differentiated thyroid cancer ([PDTC\^2]), that is or unresectable and for which standard curative measures do not exist or are no longer effective

        • ≥ 1 allowed including radioactive iodine (RAI) therapy, tyrosine kinase inhibitors (TKIs), targeted therapies, radiation therapy, chemotherapy and immunotherapy. NOTE: prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (anti-drug congigates [ADCs] is not allowed.)
        • of 2 weeks from prior anti-cancer treatments before start of study treatment (C1D1) required OR
    • anaplastic thyroid cancer (ATC)\^B

      • anaplastic thyroid cancer (ATC)\^4 that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective

        • For BRAF V600E mutated: 2 lines as TKIs and ≥ 1 line of immunotherapy allowed; all other systemic therapies, ≥ 1 line, including radiation therapy and chemotherapy;
        • wild type (WT) for BRAF: ≥ 1 line of systemic therapy allowed including TKIs, targeted therapies, radiation therapy, chemotherapy and immunotherapy
        • For both: Washout of 2 weeks from prior anti-cancer treatments before start of study treatment (C1D1) required. NOTE: prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs is not allowed.

OR

  • medullary thyroid cancer (MTC)\^C

    • medullary thyroid cancer (MTC) that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective

      • ≥ 1 line of systemic therapy allowed including TKIs, targeted therapies, radiation therapy, chemotherapy and immunotherapy. NOTE: prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs is not allowed.
      • Washout of 2 weeks from prior anti-cancer treatment before start of study treatment (cycle 1 day 1 [C1D1]) required OR
  • NUT carcinoma\^D

    • NUT carcinoma\^3 that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective

      • Any number of lines allowed. NOTE: prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs is not allowed).
      • Washout of 2 weeks from prior anti-cancer treatments before start of study treatment (C1D1) required
  • Footnote 1: Main histological types of differentiated thyroid carcinoma (DTC) include: papillary, follicular and oncocytic thyroid carcinoma. Differentiated cancers are classified as such as they tend to grow and spread slowly compared to undifferentiated cancers, which are faster growing and spread rapidly. This study is for RAIR-DTC (or RAIR PDTC) patients that have failed Radioactive iodine therapy (radioactive iodine [RAI], and those that have failed are called RAI refractory or RAIR), have metastatic or unresectable disease; original histology/cytology/pathology reports for diagnosis of DTC (or PDTC) and most recent imaging (ultrasound/CT/MRI/radioiodine imaging and recent Tg lab results) for review of disease progression and RAI uptake for RAIR determination. Also, pathology report of most recent if available.
  • Footnote 2: Poorly differentiated thyroid cancer (PDTC) is typically classified as a type of differentiated thyroid cancer (unlike an undifferentiated thyroid cancer such as anaplastic thyroid cancer4); see footnote 1.
  • Footnote 3: Patients must have histologically or cytologically confirmed NUT carcinoma based on the ectopic expression of NUT protein per World Health Organization (WHO) criteria as determined by immunohistochemistry (IHC) and/or detection of NUT gene translocation as determined by fluorescence in situ hybridization (FISH) at a Clinical Laboratory Improvement Act (CLIA) certified laboratory and/or by detection of the NUT gene translocation as determined by sequencing (e.g., dioxyribonucleic acid [DNA] next generation sequencing (NGS) or ribonucleic acid [RNA] sequencing) at a CLIA certified laboratory.
  • Footnote 4: Anaplastic Thyroid Carcinoma (ATC) is an aggressive undifferentiated tumor, the least common type of thyroid carcinoma, and develops from more differentiated tumors as a result of one or more dedifferentiating (transforming) steps leading to its fast growth and capacity to spread rapidly; in particular, via loss of the p53 tumor suppressor protein. ATC is an undifferentiated cancer that is refractory to iodine-131 (radioiodine) imaging and radioiodine therapy (RAI) and is considered RAIR and is generally incurable. The original histology/cytology/pathology reports for diagnosis of the original thyroid and for confirmation of ATC by surgical biopsy (pathology report for biopsy results) and most recent imaging (ultrasound/CT/MRI/radioiodine imaging) and recent lab results (including complete blood count [CBC], complete metabolic panel [CMP], thyroid stimulating hormone [TSH] and molecular testing) for review of disease progression.

    • Patients must have by v 1.1
    • Patients must be age ≥ 18 years
    • Patients must exhibit an (ECOG) performance status of 0-1
    • Leukocytes (white blood cell [WBC]) ≥ 3,000/mcL
    • (ANC) ≥ 1,500/mcL
    • (Hgb) ≥ 9 g/dL
    • (PLT) ≥ 100,000/mcL
    • Total ≤ 1.5 x Institutional (ULN)
    • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤ 3 x institutional ULN
    • Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN
    • Creatinine ≤ 1.5 x Institutional ULN
    • (GFR) ≥ 40 mL/min/1.73 m\^2
  • estimated glomerular filtration rate (eGFR) is estimated GFR calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation

    • The effects of enfortumab vedotin (EV) on the developing human fetus are unknown. For this reason and because ADC agents as well as other therapeutic agents used in this trial are known to be teratogenic. For this reason, patients of (POCBP) and their partners with sperm-producing reproductive capacity must agree to use adequate from time of start of study therapy (C1D1), for the duration of study participation, and for 60 days following completion of study drug therapy. Should a person of child bearing potential (POCBP) become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately. Patients with sperm-producing reproductive capacity (PWSPRC) treated or enrolled on this protocol must also agree to use adequate contraception with partners of childbearing potential from time of start of study therapy (C1D1), for the duration of study participation, and 120 days after completion of administration
  • Note: A POCBP is any patient (regardless of gender, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) with an egg-producing reproductive tract who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy
    • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally for > 12 months)

      • POCBP must have a negative pregnancy test prior to registration on study
      • Patients must have the ability to understand and the willingness to sign a written document and comply with the study requirements

Exclusion criteria

Exclusion Criteria:

  • Patients who have had prior treatment with chemotherapy, radiotherapy, biologics, agents or devices, and/or anti-cancer treatment with immunotherapy ≤ 14 days prior to planned treatment start date
  • Patients who have had prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs)
  • Patients who have had major surgery within 4 weeks of the planned date of the start of study treatment (C1D1)
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia, neuropathy and other non-significant adverse events per National Cancer Institute (NCI) (CTCAE) version (v) 6.0
  • Patients with untreated
  • Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs)
  • Patients with a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as (HbA1c) ≥ 8% or HbA1c between 7 and \< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. * NOTE: The lowest HbA1c during the screening period will be used to determine eligibility
  • Patients with a known history of (HIV).

    • NOTE: Infected patients on effective HIV anti-retroviral therapy with an undetectable HIV viral load for 6 months prior to the start of study participation are eligible to participate.
    • NOTE: and viral load are monitored per standard of care
  • Patients with a known history of chronic infection.

    • NOTE: Patients with hepatitis B virus (HBV) and an undetectable HBV viral load on HBV suppressive therapy are eligible to participate.
    • NOTE: CD4+ T cell counts, and viral load are monitored per standard of care
  • Patients with a known history of chronic infection.

    • NOTE: For patients with a known hepatitis C virus (HCV) infection who are currently on HCV treatment, are eligible if they have an undetectable HCV viral load OR
    • NOTE: Patients with an HCV infection must have been treated and cured in order to participate.
    • NOTE: CD4+ T cell counts, and viral load are monitored per standard of care
  • Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:

    • Hypertension that is not controlled on medication
    • Ongoing or active infection requiring systemic treatment

      • Routine microbial prophylaxis is allowed (e.g., uncomplicated urinary tract infections, sinus infections and are on antibiotics).
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness/social situations that would limit compliance with study requirements
    • Any other illness, laboratory finding or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints
  • Patients with a concurrent or prior malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.

    • NOTE: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or in situ cervical cancer that has undergone potentially curative therapy are allowed
  • Patients with documented history of a cerebral vascular event (stroke or ), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with Class III-IV within 6 months prior to the first dose of study drug
  • Patients who are pregnant or nursing. Pregnant patients are excluded from this study because is enfortumab vedotin has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with enfortumab vedotin breastfeeding should be discontinued if the mother is treated with enfortumab vedotin
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Treatment (enfortumab vedotin)

    Patients receive enfortumab vedotin intravenously (IV) on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, x-ray imaging or MRI and blood and urine sample collection throughout the study and optionally undergo biopsy at progression.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Enfortumab Vedotin · Procedure: Magnetic Resonance Imaging · Other: Survey Administration · Procedure: X-Ray Imaging

Interventions

  • ProcedureBiopsy Procedure

    Undergo biopsy procedure

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo blood and urine sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG 22CE, ASG-22CE, ASG22CE, Enfortumab Vedotin-ejfv, Padcev

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • OtherSurvey Administration

    Ancillary studies

  • ProcedureX-Ray Imaging

    Undergo x-ray imaging

    Also known as: Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Calculated from the first dose of study treatment to the earliest occurrence of disease progression or death from any cause, whichever occurs first. Disease progression defined as progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, other documented clinical or radiographical progression per physician judgement, or death due to disease. Will be calculated as the Kaplan-Meier estimate of the survival function at 6 months, along with the 95% confidence interval.

    Time frame: At 6 months

Secondary outcomes

  1. Objective response rate

    Defined as the proportion of patients who achieve a complete response or partial response as per RECIST v 1.1. The proportion of evaluable patients experiencing an objective response will be estimated with a 95% exact binomial confidence interval. The confidence interval will be adjusted for the sequential nature of the two-stage procedure.

    Time frame: From the time of baseline imaging until the radiographic response has been confirmed, the patient experiences disease progression, or initiates subsequent anti-cancer therapy, up to 1 year

  2. PFS

    Will calculate the proportion of patients alive and without progression as described: Disease progression defined as progressive disease per RECIST v 1.1, other documented clinical or radiographical progression per physician judgement, or death due to disease. PFS will be analyzed using the Kaplan-Meier method. The overall (median) PFS estimate will be reported along with the confidence interval.

    Time frame: From the first dose of study treatment to the earliest occurrence of disease progression or death from any cause, whichever occurs first, up to 1 year

  3. Overall survival (OS)

    Calculated from the start of trial therapy until the patient completes study follow up participation or experiences death from any cause. Will be analyzed using the Kaplan-Meier method. The median OS estimate at 6 months will be reported along with the confidence interval.

    Time frame: At 6 months

  4. OS

    Overall survival will be analyzed using the Kaplan-Meier method. The median OS estimate will be reported along with the confidence interval.

    Time frame: From the start of trial therapy until the patient completes study follow up participation or experiences death from any cause, up to 1 year

  5. Incidence of adverse events

    Will collect and report the frequency of adverse events by type, severity (grade), timing and attribution to enfortumab vedotin, according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0.

    Time frame: Up to 1 year

  6. Changes in quality of life

    Assessed per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Thyroid Cancer Module.

    Time frame: Up to 1 year

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for May 2030, 36 months later.

Of 26 phase 2 interventional studies under Thyroid Carcinoma, Anaplastic, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 112. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
May 5, 2027
Primary completionEst.
May 5, 2030
CompletionEst.
May 5, 2031
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07863765
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
May 5, 2027 (estimated)
Primary completion
May 5, 2030 (estimated)
Completion
May 5, 2031 (estimated)
Last update
Oct 7, 2026

Study contacts

Study Coordinator
Contact
cancer@northwestern.edu
3126951301
Jochen H Lorch, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enfortumab vedotin

Start the discussion